RCMNY
BCYC

Rubric Capital Management (New York)’s Bicycle Therapeutics BCYC Stock Holding History

Rubric Capital Management (New York)’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-205,423
Closed -$4.16M – 66
2024
Q2 		$4.16M Hold
205,423
– – 0.11% 62
2024
Q1 		$5.12M Hold
205,423
– – 0.15% 64
2023
Q4 		$3.71M Hold
205,423
– – 0.08% 53
2023
Q3 		$4.13M Hold
205,423
– – 0.15% 57
2023
Q2 		$5.24M Hold
205,423
– – 0.22% 54
2023
Q1 		$4.37M Buy
+205,423
New +$5.15M 0.11% 64

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Rubric Capital Management (New York)'s BCYC Position: Q3 2024 in Review

Rubric Capital Management (New York) sold out of Bicycle Therapeutics (BCYC) in Q3 2024, closing a stake of 205,423 shares — an estimated $4.16M sold.

Rubric Capital Management (New York) first reported a position in BCYC in Q1 2023 and held it in 6 quarters. The position peaked at $5.24M in Q2 2023. 105 funds tracked by Wall St. Rank hold BCYC as of Q3 2024.

  • Rubric Capital Management (New York) reported no remaining Bicycle Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 205,423 Bicycle Therapeutics shares in Q3 2024, an estimated $4.16M.
  • Rubric Capital Management (New York) first reported a position in Bicycle Therapeutics in Q1 2023 and held it in 6 quarters.
  • Rubric Capital Management (New York)'s Bicycle Therapeutics position peaked at $5.24M in Q2 2023.
  • 105 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q3 2024.

Based on Rubric Capital Management (New York)'s 13F filing for Q3 2024, filed 13 Nov 2024.